News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Accelrys Inc. (ACCL) Fast-tracks Scientific Innovation with Modeling and Simulation Software Release


6/21/2012 10:14:13 AM

BRUSSELS, June 20, 2012 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading scientific enterprise R&D software and services company, today announced the release of Accelrys Discovery Studio® 3.5 modeling and simulation software during the company's European Science Symposium in Brussels. The latest release extends Discovery Studio's portfolio of small-molecule ligand design and market-leading biological simulation tools, including a new, validated ligand-profiling database for drug repurposing studies, new science to assess the development potential of putative biologics and many additional enhancements that help deliver a highly effective life sciences modeling and simulation environment.

To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/accelrys-fast-tracks-scientific-innovation-with-modeling-and-simulation-software-release-159617375.html

New, validated science built upon active, ongoing partnerships is the keystone underlying the latest Discovery Studio 3.5 release. Discovery Studio's new ligand-profiling solution uses a spatial aggregation propensity algorithm and Developability Index licensed from the Massachusetts Institute of Technology (MIT) and validated in collaboration with Novartis Pharma AG. Capabilities such as these provide important indicators of whether ligands and proteins will be good candidates for downstream development.

"The current economic squeeze on scientific resources across industries is counterbalanced by a continuing critical need for scientific innovation and excellence," said Senior Vice President and Chief Technology Officer Dr. Matt Hahn. "Deploying Discovery Studio modeling and simulation software on the scientifically aware Accelrys Enterprise Platform can help organizations meet the critical performance, cost and innovation goals that define today's increasingly information-driven R&D environments."

Discovery Studio 3.5 accelerates innovative modeling and simulation workflows by providing:

  • New science supporting small-molecule ligand design including a new ligand-profiling database for drug repurposing and side-effect studies; new in situ lead optimization and core-hopping tools for fragment-based drug design; and new activity cliffs and activity effects analysis based on Matched Molecular Pairs analysis
  • New science supporting biotherapeutics including new calculations for ranking protein-protein aggregation and improved capability to perform pH-dependent mutation energy (binding) calculations
  • Up-to-date Scientific Collections, enabling organizations to build, deploy, analyze and report on complex scientific data types using the Accelrys Enterprise Platform
  • Updated partner ecosystem includingsupport for the latest releases of CHARMm molecular simulation software and the MODELER program for comparative protein structure modeling
  • Enhanced usability, accessibility and visualization including enhanced generation of receptor-ligand interaction surfaces and improved display and rendering of 3D molecular objects

Discovery Studio provides comprehensive modeling and simulation capabilities for computational chemists, computational biologists and other scientists engaged in either small or large molecule life sciences R&D. The software speeds innovation, reduces costs, enhances productivity and improves outcomes through the automation and expert use of predictive science.

To learn more about the latest Discovery Studio release, register for the webinar, "What's New in Discovery Studio 3.5," scheduled for Wednesday, June 27.

About Accelrys, Inc.

Accelrys (NASDAQ:ACCL), a leading scientific enterprise R&D software and services company, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad, flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.

Accelrys solutions are used by more than 1,300 customers in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, Calif., Accelrys employs more than 200 full-time PhD scientists. For more information about Accelrys, visit www.accelrys.com.

Related Links
Accelrys's Discovery Studio

SOURCE Accelrys, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES